Introduction and Objective: This study examines changes in treatment satisfaction and glycemic outcomes in people with type 1 diabetes (PwT1D) transitioning from multiple daily injections (MDI) to continuous subcutaneous insulin infusion (CSII) with the tubeless Accu-Chek Solo micropump.Methods: CSII-naive PwT1D from Argentina (n=50) were enrolled in a multi-center, prospective, single-armed study using Accu-Chek Solo with a total duration of four years. This report shows outcomes at 13 weeks as well as annually up to three years. The primary outcome was the change in treatment satisfaction after 13 weeks using the Diabetes Technology Questionnaire (DTQ). Secondary outcomes included annual changes in DTQ, HbA1c and safety parameters.Results: After 13 weeks, the DTQ “Impact and satisfaction” change score was 113.4±16.7, (mean±SD, 90=non-change score, p<0.0001). Significant improvement in satisfaction was sustained after one, two and three years (111.4±14.4, p<0.0001; 108.4±14.9, p=0.0008; 110.0±12.8, p=0.0005). HbA1c decreased from 8.2%±1.3% to 7.9%±1.2% (p=0.038) after 13 weeks, and to 7.9%±1.3% (p=0.047), 8.0%±1.3% (p=0.172) and 7.9%±1.2% (p=0.128) after one, two and three years respectively. A total of seven severe hypoglycemic events and one diabetic ketoacidosis were reported.Conclusion: Transitioning from MDI to CSII with Accu-Chek Solo resulted in a significant improvement of users’ treatment satisfaction which was sustained for three years. In addition, HbA1c significantly decreased within the first year and remained stable. These findings suggest a dual benefit of improved satisfaction and glycemic control as well as a favorable safety for PwT1D using Accu-Chek Solo.
A. Dain: None. N. Dagenbach: Employee; Roche Diabetes Care. G. Vogt: Employee; Roche Diabetes Care. T.J. Etter: Employee; Roche Diabetes Care. S. Moceri: Employee; Roche Diabetes Care.
Source link
Leave a Reply